Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Blood (2024) 144 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2024-193960

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blood (2022) 140 (Supplement 1): 6631–6632.

https://doi.org/10.1182/blood-2022-159695

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Blood (2021) 138 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2021-147467

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Romain Guieze, MD, Loic Ysebaert, MD PhD, Lysiane Molina, MD, Damien Roos-Weil, MDPhD, Anne-Sophie Michallet, MD PhD, Benedicte Hivert, MD, Julie Gay, MD, Alain Saad, MD, Luc Mathieu Fornecker, MD PhD, Julien Broséus, Valérie Rouille, Laëtitia Auvray, Alain Jacques Delmer, MD PhD, Pierre Feugier, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-136667

Published: 2020

Journal Articles

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Pedro H Prata, MD, Cecile Bally, Thomas Prebet, MD PhD, Christian Recher, MD PhD, Geoffroy Venton, Xavier Thomas, MD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Thomas Cluzeau, MDPhD, Judith Desoutter, Julie Gay, Claude Preudhomme, PharmD, PhD, Pierre Fenaux, MD PhD, Lionel Ades, MD PhD

Blood (2017) 130 (Supplement 1): 1335.

https://doi.org/10.1182/blood.V130.Suppl_1.1335.1335

Published: 2017

Journal Articles

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

Blood (2014) 124 (21): 482.

https://doi.org/10.1182/blood.V124.21.482.482

Published: 2014

Journal Articles

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Miguel Hie, Julie Gay, Lionel Galicier, François Provôt, Claire Presne, Pascale Poullin, Guy Bonmarchand, Alain Wynckel, Ygal Benhamou, Philippe Vanhille, Aude Servais, Dominique Bordessoule, Jean-Philippe Coindre, Mohamed Hamidou, Jean-Paul Vernant, Agnès Veyradier, Paul Coppo, the French Thrombotic Microangiopathies Reference Centre

Blood (2014) 124 (2): 204–210.

https://doi.org/10.1182/blood-2014-01-550244

Published: 2014

Includes: Supplemental data

Journal Articles

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Miguel HIE, MD, Julie Gay, MD, Lionel Galicier, MD, Francois Provot, Sandrine Malot, Pascale Poullin, MD, Guy Bonmarchand, MD, Alain Wynckel, MD, Ygal Benhamou, MD, Philippe Vanhille, Dominique Bordessoule, MD, PhD, Jean-Paul Vernant, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD

Blood (2013) 122 (21): 448.

https://doi.org/10.1182/blood.V122.21.448.448

Published: 2013

Journal Articles

Efficacy and Safety Profile of Long Term Exposure to Lenalidomide in Relapsed Multiple Myeloma.

Guillemette Fouquet, MD, Stéphanie Tardy, MD, Helene Demarquette, MD, Sarah Bonnet, MD, Julie Gay, MD, Houria Debarri, MD, Charles Herbaux, MD, Jessica Michel, MD, Aurore Perrot, MD, Caroline Serrier, MD, Suzanne K. Robinson, PhD, Darko Miljkovic, Pascale Morel, Catherine Boccacio, Herve AvetLoiseau, MD, Thierry Facon, MD, Cyrille Hulin, MD, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 2964.

https://doi.org/10.1182/blood.V120.21.2964.2964

Published: 2012

Journal Articles

IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma

Eileen Mary Boyle, MD, Philip Young, Helene Demarquette, MD, Julie Gay, MD, Houria Debarri, MD, Sarah Bonnet, MD, Charles Herbaux, MD, Remy Dulery, MD, Salomon Manier, MD, Jean-Luc Faucompre, Frederic Combat, MD, Annie Pietrantuono, MD, Brigitte Onraed, Bernadette Hennache, Thierry Facon, MD, Stephen J Harding, MD, PhD, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 3970.

https://doi.org/10.1182/blood.V120.21.3970.3970

Published: 2012

Journal Articles

Early Human Herpes Virus Type 6 Reactivation in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT).

Remy Dulery, Anny Dewilde, Julie Gay, MD, Julien Rossignol, Louis Terriou, Valerie Coiteux, MD, Jean-Pierre Jouet, MD, Ibrahim Yakoub-Agha, MD, PhD

Blood (2009) 114 (22): 794.

https://doi.org/10.1182/blood.V114.22.794.794

Published: 2009

Journal Articles

Early Response Using Serum Immunoglobulin Free Light Chain (sFLC) Measurement Predicts Response to Therapy in Waldenstrom Macroglobulinemia (WM)

Xavier Leleu, MD, PhD, Aldo M. Roccaro, MD, PhD, Renee Leduc, Stephanie Poulain, MD, Anne-Sophie Moreau, MD, Julie Gay, MD, Remy Dulery, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD

Blood (2008) 112 (11): 3755.

https://doi.org/10.1182/blood.V112.11.3755.3755

Published: 2008

NARROW

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Efficacy and Safety Profile of Long Term Exposure to Lenalidomide in Relapsed Multiple Myeloma.

IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma

Early Human Herpes Virus Type 6 Reactivation in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT).

Early Response Using Serum Immunoglobulin Free Light Chain (sFLC) Measurement Predicts Response to Therapy in Waldenstrom Macroglobulinemia (WM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only